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1. Introduction 
The term cancer is used generically to represent a set of more than 100 diseases, including 
malignant tumors from different locations. The understanding, diagnosis and management 
of malignancies require scientific knowledge and experiences ranging from the knowledge 
of the complex epigenetic mechanisms (intracellular regulation) to the individual lifestyle 
choice in different societies. Therefore, cancer prevention, prognosis and control are issues 
of profound importance to global public health. 
Cancer appears as a major public health problem both in developed and developing 
countries. According to the latest report from the International Agency for Research on 
Cancer (IARC) / WHO (Boyle & Levin, 2008), the overall impact of cancer more than 
doubled in 30 years. About 12 million cancer cases and 7 million cancer deaths are estimated 
to have occurred in 2008. Of these, lung cancer had the greatest incidence rate (1.52 million 
new cases), followed by breast cancer (1.29 million cases) and colorectal cancer (1.15 million 
cases).  Due to poor prognosis, lung cancer was the leading cause of death (1.31 million), 
followed by stomach cancer (780,000 deaths) and liver cancer (699,000 deaths About one 
million new cancer cases and 589,000 cancer deaths are estimated to have occurred in South 
America, Central America and in the Caribbean. Prostate cancer was the most common 
cancer in men, followed by lung, stomach and colon and rectum. Breast cancer was the most 
common cancer in women, followed by cancers of the cervix, colon and rectum, stomach 
and lung (Boyle & Levin, 2008). 
The continued population growth and ageing significantly affect the impact of cancer in the 
world, which is greater in developing and under-developed countries. Half of the world’s 
new cancer cases and about two thirds of cancer deaths are estimated to have occurred in 
2008 in these countries (Farmer et al., 2010). Therefore, it is essential that resources and 
efforts are directed towards guiding strategies for cancer prevention, diagnosis and 
treatment. 
In this particular chapter the strategies for prevention, diagnosis and treatment in the 
current epigenetic scenario of the new molecular mechanisms proposed for the 
development of cancer will be discussed. 
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2. Epigenetics  
Epigenetics is the study of heritable changes in phenotype or gene expression caused by 
mechanisms other than changes in DNA sequence. The molecular mechanisms of epigenetic 
inheritance and its relationship with the expression of chromatin include three interrelated 
processes, namely DNA methylation, genomic imprinting and histone modifications 
(Kouzarides, 2007). Through small chemical molecules called methyl groups, which bind 
covalently with DNA or histones, the epigenetic processes improve the ability of genome to 
store and transmit biological information beyond the known structure and sequence of 
genetic material. 
In recent years we have faced a new paradigm, a view more focused on the cell and on the 
search for information layers outside of the cell nucleus and even of the DNA as the center 
for information of the cell. These layers of epigenetic information transcend embryogenesis 
and cancer development processes, as follows.  
3. The embryogenesis as an epigenetic process  
The importance of epigenetics in experimental biology is decisively felt in the process of cell 
differentiation. The information and epigenetic marks are essential to determine which cell 
is phenotypically different from any other cell as a result of embryogenesis. This allows us 
to reprogram a somatic cell and transform it based on epigenetic principles, in a cell with 
characteristics of pluripotent stem cells. These cells are called ips cells (induced pluripotent 
stem cells)(Takahashi et al., 2007). In the Ips cells the DNA has not been changed or 
modified and the pluripotent state can be inherited during each cell division. This indicates 
that the changes in the machinery of epigenetic information, rather than genetic material, 
play a decisive role in controlling differentiation. 
4. The cancer as an epigenetic process 
The process of cancer development involves genomic changes identified as genetic and also 
changes in the epigenetic information (Jones & Baylin, 2002; Hake et al., 2004; McGarvey et 
al., 2008). Altered DNA methylation patterns have been described and histone modifications 
in cancer cells may occur at different stages of tumor development and contribute to the 
development and progression of cancer (Galm et al., 2006; McGarvey et al., 2008). 
Historically, the first evidence has emerged that the contribution of epigenetics to cancer 
development comes from nuclear transfer experiments. Nuclear transfer provides a tool for 
selective reprogramming of the epigenetic state of a cell genome, without changing their 
genetic constitution, with the purpose of assessing the role of epigenetics in tumorigenesis. 
Experiments with frogs have shown that renal carcinoma nuclei can be reprogrammed to 
support embryonic development at the tadpole stage (McKinnell et al. 1969). Similar results 
were also obtained with nuclei from medulloblastoma in mice (Li et al. 2003). Therefore, the 
nuclei of cancer cells can be reprogrammed through a process of nuclear transfer. 
Another experimental approach was also based on nuclear transfer with blastocyst 
formation. However, it included the creation of explants from the inner cell mass in "in 
vitro" culture to develop embryonic stem cell lines (Hochedlinger et al., 2004). These 
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embryonic stem cells were used to confirm the origin of the tumor clone and test the initial 
conservation of the tumorigenic capacity of these cells originated by tumor cores.  In these 
experiments it has been unequivocally demonstrated that the clones derived from cancer 
cells and that the nuclei of cancer cells (leukemia, lymphoma and breast cancer) were able to 
sustain the embryonic development until the preimplantation blastocyst stage. It has also 
been demonstrated that the oocyte cytoplasm is able to reprogram the epigenetic state of 
some nuclei of tumor cells, transforming these cells into pluripotent and also enabling them 
to sustain the differentiation of multiple somatic cell types such as melanocytes, 
lymphocytes and fibloblasts. Therefore, the cancer state is an epigenetic cell state susceptible 
of change regardless of the DNA alterations (Feinberg, 2008). 
The role of epigenetics was also confirmed by studying cohorts of twins and analyzing the 
concordance in cancer between monozygotic and dizygotic twins, and, thus, providing 
information about whether family patterns are influenced by environmental or genetic 
patterns. If the concordance in cancer is greater between monozygotic twins (who share 
100% of the genes) than between dizygotic twins (who share in average 50% of the 
segregated  genes) the genetic effects are probably more important. On the other hand, if the 
concordance rate is similar in both types of twins, then the environmental effects are 
probably more important. Thus, the use of statistics to analyze large populations of twins 
allows us to estimate the magnitude of environmental and genetic effects on susceptibility to 
sporadic cancer. 
This retrospective study has shown that hereditary factors make a minor contribution to 
susceptibility to most types of neoplasms, indicating that the environment plays a major role 
in sporadic cancer in populations living in the study areas (Lichtenstein et al., 2000).  The 
study, on the other hand, stresses that some types of cancer, such as prostate and colorectal 
cancers are more influenced by genetic factors than previously thought. 
Thus, even more important aspects related to diseases are being reworked, and cancer may 
no longer be categorized as a disease based on genetics alone, and all the data indicate that 
most commonly diagnosed cancers in the world have primarily environmental or epigenetic 
origin. Except for some types of cancer considered hereditary, familial adenomatous 
polyposis, colorectal cancer and prostate cancer, the contribution of hereditary factors to the 
development of cancer is thought to be relatively small. 
5. How the epigenetics affects genetics  
The DNA methylation takes place only at cytosine bases that are located 5’ to a guanosine in 
a CpG dinucleotide. This dinucleotide is actually underrepresented in the genome, but short 
regions, known as CpG islands, are rich in CpG content. Most CpG islands are found in the 
proximal promoter regions of almost half of the genes in the mammalian genome and are, 
generally, unmethylated in normal cells. In cancer, however, the hypermethylation of these 
promoter regions is now the most well categorized epigenetic change to occur in tumours, it 
is found in virtually every type of human neoplasm and is associated with the inappropriate 
transcriptional silencing of genes, involving tumour-suppressor genes.  
These tumour suppressor genes are predicted to be important for tumorigenesis, but seem 
not to be frequently mutated and de novo hypermethylation of CpG islands in the promoters 
of MLH1 (mutL homologue 1, colon cancer, non-polyposis type 2) (Herman et al., 1998) and 
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Author Organ/tissue 
Genes 
studied 
Altered genes-aberrant methylation-aberrant 
Distribution (p) 
Herman et al., 1995 Many Cancers p16 p16 - Hypermethylation (the first evidence) 
Herman et al., 1998 Colorectal hMLH1 hMLH1-Hypermethylation (p < .001) 
Esteller et al., 2000 Breast, Ovary BRCA1 BRCA1- Hypermethylation (p < .0002) 
Esteller et al., 2000 Colorectal hMGMT MGMT (k-RAS)-Hypermethylation (p= .002) 
Cho et al., 2003 Stomach CAGE CAGE- Hypomethylation 
Russo et al., 2005 Lung/Blood p16/DAPK p16/DAPK - Hypermethylation (p = .001) 
Sinha et al., 2009 Tongue p16 p16- Hypermethylation (p =.0361) 
Tanemura et al., 
2009 Skin RASSF1A RASSF1A- Hypermethylation (p < .005) 
Daí et al., 2009 Lung Kaiso kaiso- Cyoplasmic distribution (p = .005) 
Kim et al., 2010 Intestine p16/MINT31 
Hypermethylation- p16 (p < .0001) MINT31 
 (p < .004) 
Muggerud t al., 2010 Breast RASSF1A RASSF1A- Hypermethylation (p < .001) 
Taghavi et al., 2010 Esophagus p16 p16 - Hypermethylation (p <.001) 
Table 1. Summary of epigenetic modifications associated with human cancers (prospective 
and retrospective studies). 
MGMT (O6-methylguanine-DNA methyltransferase) (Esteller et al., 2000b), seems to be that 
leads to their inactivation. Hypermethylation of the promoter of MLH1 can lead to 
microsatellite instability, and hypermethylation of the promoter of MGMT leads to 
increased G →A transitions. Additionally, there is a growing list, of other tumour 
suppressor genes in which promoter hypermethylation is the only mechanism for the loss of 
function of these genes in tumorigenesis: breast cancer 1, early onset (BRCA1) (Esteller et al., 
2000a), von Hippel–Lindau syndrome (VHL)(Herman et al., 1994), p16 (Herman et al., 1995; 
Russo et al., 2005; Sinha et al., 2009; Kim et al., 2010; Taghavi et al., 2010), death associate 
protein (DAP) kinase 1 (DAPK1) (Russo et al., 2005), and RASSF1A (Tanemura et al., 2009; 
Muggerud et al., 2010), which encodes a protein of unknown function that can bind to the 
RAS oncogene (Table 1).  
The epigenetic modifications can also be induced by environmental and occupational 
exposures thus contributing to carcinogenesis. A good example is the methylation changing 
the absorption wavelength of cytosine, into the range of incident sunlight, resulting in CC 
→TT mutations, which commonly occur in skin cancers (Pfeifer et al., 2000). So, tobacco 
smoke has been estimated to account for 30% of all cancer deaths and 85% of lung cancer 
deaths due to the presence of thousands of mutagenic compounds, including polycyclic 
aromatic hydrocarbons and nitrosamines. In this case, methylated CpGs are also preferred 
binding sites for benzo(a)pyrene diol epoxide and other carcinogens that are found in 
tobacco smoke (Yoon et al., 2001). These cause DNA adducts and G →T transversion 
mutations, which are often found in the aerodigestive tumours of smokers (Ziech et al., 
2010). On the other hand, one of the most well established occupational carcinogenic agents 
is asbestos along with a growing list of tumorigenic agents that include: wood-dust 
particulates, solvents, paints, dye products, gasoline, petroleum-based mixtures, benzenes, 
mineral oils, phthalates and metal ions (Ziech et al., 2010). For these agents, the free radical-
induced damage is suggested to be involved in aberrant epigenetic changes observed during 
the carcinogenic process. The understanding of epigenetic alterations has become clearer the 
mechanism by which lifestyle choice like smoking and drinking, diet, environment and 
infections affecting the DNA tissue-specific cells and altering the behavior of cells in this 
tissue. 
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Finally, besides DNA hypermethylation, cancer cells have also been shown to undergo 
dramatic global hypomethylation (Ehrlich, 2002; Cho et al., 2003) and changes in the 
organization of the histone protein complex that would serve as epigenetic biomarkers 
indicative of the carcinogenic process (He and Lehming, 2003). Many references in the 
literature published in the last years reviewed the importance of alterations in DNA 
methylation and histone modifications for better cancer diagnostics and therapeutic 
strategies (Jones and Baylin, 2002; Ziech et al., 2010; table 1).  Further review of this subject is 
not within the scope of this chapter, which is aimed to show the role of proteins, like Kaiso, 
which interact with methylated DNA and participate in the establishment of cancer, as we 
shall see later in this chapter. 
6. The epigenetics and proteomics walking together toward the diagnosis 
and prognosis of cancer, in the current epigenetic context 
A major challenge faced by cancer therapy is to be able to predict the early stage of the 
disease in order to provide an appropriate treatment for the patient (Ludwig and Weinstein, 
2005). In this regard, the molecular biomarkers have been useful for distinguishing different 
subtypes of patients with different clinical profiles and at all stages of disease, expanding 
our prognostic ability (Seligson et al., 2005). 
Over the past decades high-throughput technologies including genomics, epigenome, 
transcriptome and proteomics have been applied to improve our understanding of cancer 
pathogenesis in order to develop strategies aimed to improve cancer treatment (Seligson, 
2005; Ocak et al., 2009). The ultimate goal of these technologies is to help develop 
noninvasive methods for specific and sensitive diagnosis and facilitate prediction of the 
response of a patient to a given therapy, as well as help identify potential therapeutic targets 
(Ueda et al., 2011). 
The most important technologies used in the study of cancer are proteomics and 
epigenomics that help understand that cancer cell phenotype is primarily determined by 
proteins, and, thus, a genomic or transcriptome approach of the disease are extremely 
limited. This can be said because it is known that i. levels and protein expression have a low 
correlation with mRNA levels, ii. proteins undergo post-translational modifications that 
may alter its function, iii. in the same cell can express different proteins using a mechanism 
of differential splicing from the same mRNA and very important as we shall see iv. the same 
protein may have a different function depending on the cellular compartment where it is 
located. Therefore, the protein detection techniques, including immunohistochemistry 
(IMH), in this new context, are of vital importance for understanding cellular processes and 
disease emergence. 
In order to better understand the cancer cell and the development of cancer, proteomic 
information projects have been created based on epigenetics in which proteins and their 
interactions with the epigenome inside the cell become the key aspect in the understanding 
of how cancer cells work (Stefanska et al., 2011; Jerónimo et al., 2011). Therefore, knowledge 
of machinery and all the protein interactions established by them may be important for the 
prognosis of the tumor and the development of a proper drug to fight cancer and to 
determine the mechanisms of the disease. 
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A good example is the study of the proteins of the methyl-CpG-binding domain (MBD) that 
"read" and interpret the signals in DNA methylation and are critical mediators of various 
epigenetic processes. We currently know that the family of MBD proteins is formed by five 
MBD1 and MeCP2 -4 members. There is also a member of non-classical MBD protein called 
Kaiso that uses a "zinc finger" domain to bind to methylated DNA and mediate 
transcriptional repression. The factor Kaiso and its partner p120ctn are considered similar to 
the ǃ-catenin-TCF/LEF (T-cell factor / Lymphoid Enhancing factor) pair that regulate genes 
of canonical Wnt pathways, with the peculiarity that Kaiso (the difference in TCF/LEF) can 
interact with the epigenome in cancer development. As usually, hypermethylation is a 
recognized gene silencing mechanism in processes of tumorigenesis and drug resistance.  
Obviously, the MBD protein and Kaiso could be important modulators of tumorigenesis and 
excellent therapeutic targets for developing anti-cancer therapies (Sansom et el., 2007). 
Therefore, the role of protein detection methods in the diagnosis, prognosis and even in the 
development of therapies against cancer is unquestionable in the current epigenetic scenery 
of disease etiology (Yoshimura et al., 2011).  
7. The multifunctional protein and its relation to cellular compartments 
A single protein can have different functions in a cell and these functions concern the 
compartment where they are located. One of the best documented examples is that 
transglutaminase 2 (TG2) may act as a transglutaminase, G-protein kinase, protein disulfide 
isomerase or as an adapter protein. These multiple biochemical activities are involved in a 
wide variety of cellular processes such as differentiation, cell death, inflammation, cell 
migration and others. The specific microhabitats and subcellular compartments of location 
of the plasma membrane, cytoplasm, nucleus, mitochondria, or extracellular space are 
important in the development of different biochemical activities by the same protein 
structure (Park et al., 2010). 
Thus, in our search for a drug target, e.g., cancer, we must always know the location of a 
given protein in the cell and be aware of how this cell places these proteins in different 
micro environments, and that more often than not these different functions may occur 
simultaneously. So part of the strategy to find the correct pharmacological targets is the 
previous understanding of the structure and the establishment of subcellular 
microenvironments inside the cells and the better knowledge of the complex and dynamic 
subcellular compartmentalization that will be further explained. 
Therefore, immunohistochemistry provides information that cannot be obtained in any 
other way, which is the relationship between the pathological state and the dimension of the 
altered compartment (Oliver and Jamur, 2009; Dabbs, 2010), of great relevance to the 
establishment of the cancer diagnosis, as we shall see soon.  
8. The multifunctional proteins, compartments and cancer 
Surprisingly, over the past few decades multifunctional proteins provided the basis of the 
study of some diseases, including cancer. Alterations and aberrations of the multifunctional 
proteins regarding their distribution and subcellular localization have been used to diagnose 
the pathological state. I will consider briefly connexins, ǃ-catenin and kaiso as examples of 
these proteins and their role in cancer development. 
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9. Connexins 
Connexins can be channels of intercellular communication or proteins that trigger processes 
of proliferation or apoptosis, depending on the cellular context (Goodenough & Paul, 2003). 
Traditionally, it was believed that the role of connexins in cancer development was related 
to its role in intercellular communication channel or gap junctional intercellular 
communication activity (GJIC). In fact, cancer was the first disease to be associated with 
connexin disorders (Loewenstein, 1979). The evidence was mainly related to the use of 
tumor-promoting agents (non-mutagenic carcinogens) and mitogens that decreased the 
activity of connexin-mediated intercellular communication (Budunova & Williams, 1994) 
and, on the other hand, antineoplastic agents or chemicals promoting cell coupling through 
these proteins (King & Bertram, 2005). It was also shown that tumor-derived cells were 
deficient in expression of connexins (Lee et al., 1992; Laird et al., 1999) and that studies of 
overexpression of these proteins showed decrease in cellular proliferation (Yamasaki & 
Naus, 1996). This created a favorable scenario that could lead one to believe that the 
decrease in expression of connexins and, thus, intercellular communication, was related to 
cell proliferation and tumor progression. 
The most important work on the change in concepts regarding these channels of 
communication was the transfection of connexin43 that makes it possible reversing the 
neoplastic phenotype of a strain of human glioblastoma cells and that showed that 
phenotypic reversion was associated with a cytoplasmic localization of connexins without 
increasing the ability to establish intercellular communication between cells (Huang et al, 
1998). Therefore, a new concept has arisen, according to which connexins could have two 
different functions not necessarily connected: (i) intercellular communication in the plasma 
membrane and (ii) direct modulation of cell growth control in cell cytoplasm. 
Concerning the connexin role in regulating cell proliferation, two hypotheses have been 
developed:  1) a downregulation of connexins from the plasma membrane is an indirect 
result of the activation of MAPK (mitogen-activated protein kinase) and Akt 
(phosphoinositide-activated kinase) and 2) they act as negative regulators of intercellular 
junctions (Kojima et al., 2004). However, other lines of evidence indicated that the connexins 
were directly involved in the regulation of cell growth and that its downregulation would 
contribute to (and not be a consequence of) the loss of cell cycle control (Vinken et al., 2006).   
A detailed study supporting this latter idea used transfection of connexin 43 in human 
osteosarcoma cells, which inhibited cell proliferation without restoring intercellular 
communication (Zhang et al., 2001). In this model direct connexin 43 changes the expression 
of p27/Kip1 (the cyclin-dependent kinase inhibitor). Importantly, Cx43, or at least the 
carboxy terminal tail of this protein has been localized within the nucleus with the use of 
immunohistochemistry, confirming an intracellular regulatory role (Dang et al., 2003; Cofre 
& Abdelhay, 2007). 
In primary breast tumors, immunohistochemistry can clearly detect the cytoplasmic 
expression of connexins 43 and 26, being a commonly used diagnostic test for this stage of 
the disease (Kanczuga-koda et al., 2006). However, immunohistochemistry shows that in the 
same metastatic tumor cells taken from the lymph node, the expression of connexin43 and 
26 changes and has now expanded, though in the plasma membrane. This increased 
expression in the cell membrane is considered the earliest event in the process of metastasis 
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(Kanczuga-koda et al., 2006). The important diagnostic value of IMH is evident in the 
resolution stage of the disease. 
Although the role of connexins in the process of metastasis is controversial because some 
studies indicate that connexin expression is inversely proportional to metastatic capacity of 
a primary tumor (Nicolson et al., 1988), other studies reveal that connexins might be 
involved in metastasis (Carystinos et al., 2001). 
At least it is clear that, unlike previously thought, connexins have a tumor suppressor 
function, but not from a classical point of view, since there are no mutations of this protein 
associated with carcinogenesis.  So, they seem to have different effects on different stages of 
carcinogenesis, (depending on the connexin isoform or cell type in which it is expressed). 
Connexins seem to favor cell proliferation when they are downregulated (cytoplasmic 
localization) and increase the potential for invasion and metastasis when they are 
overexpressed (initially in the plasma membrane) (for a review of this literature sees 
Crespin et al., 2008). As we shall see at the end of this chapter, this issue needs to be clarified 
for a better understanding of subcellular compartmentalization and mechanisms of 
regulation of intracellular signaling.   
10. β-catenin 
The decisive factor in paradigm change regarding proteins with various compartments  
inside the cell and its relationship with the processes of disease establishment was ǃ-catenin. 
The protein ǃ-catenin is a transcriptional factor with nuclear function and also a structural 
component of tight junctions (adherens junctions) in the plasma membranes of the cell. The 
role of cell adhesion was the first to be characterized and such role is possible because ǃ-
catenin interacts with cadherins and with the actin cytoskeleton via an adapter protein ǂ-
catenin (Kemler, 1993)(Figure 1a). The transcriptional function developed as part of the 
intracellular pathways of the canonical Wnt. In the nucleus ǃ-catenin acts as a cofactor along 
with TCF/LEF in the upregulation of a variety of oncogenes including cyclin D1 and c-myc 
(Figure 1d). The canonical Wnt/Wingless signaling pathway plays an important role in 
embryonic development and tumorigenesis (Morin, 1999; Polakis, 2000; Bienz, 2005). 
The transcriptional role of ǃ-catenin is very interesting because it involves translocation 
from the cytoplasm to the nucleus and initiates the expression of its target genes within it 
(Nusse, 1997; Akiyama, 2000). In the absence of Wnt binding a macromolecular complex 
formed by the cytoplasmic protein APC (adenomatous polyposis coli), Axin and disheveled 
(DSH) stimulate the phosphorylation of ǃ-catenin. Directly responsible for this 
phosphorylation is the protein casein kinase 1 (CK1) and glycogen synthase kinase 3 (GSK3). 
Β-catenin phosphorylated is destined to a ubiquitin-mediated degradation of ǃ-catenin 
(Figure 1 b). So, in the absence of Wnt signaling levels of ǃ-catenin are kept low by the 
action of Gsk3 and CK1 (Clevers, 2006; McDonald et al., 2009). 
Translocation of ǃ-catenin only happens when the receptors of the canonical Wnt pathways 
are activated and the macromolecular complex is recruited to the plasma membrane 
proteins with CK1 and GSK3 and thus could not phosphorylate ǃ-catenin (Figure 1 c). The 
key point in this model is that the activation of canonical pathway leads to stabilization of ǃ 
catenin. Therefore, Wnt signaling would finally prevent ǃ-catenin degradation, which could 
then translocate to the nucleus and perform its transcriptional activity (Clevers, 2006). As we 
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shall see later, this classical interpretation may change when additional information on 
subcellular compartmentalization is gained. 
In clinical practice aberrant changes in the expression of ǃ-catenin in the nucleus have made 
it possible to suggest the use of this molecule as a complement to the differential diagnosis 
of various cancers, including cancers of the gastrointestinal tract, lung and tumors of 
gynecological origin (Montgomery & Folpe, 2005). Also, the absence or loss of nuclear 
expression of ǃ-catenin expression associated with strong cytoplasmic P-cadherin was 
associated with melanoma aggressiveness and poor patient survival, establishing an 
important prognostic value in these types of cancer for ǃ-catenin (Bachmann et al., 2005). 
 
Fig. 1. Canonical and non-canonical Wnt signaling pathway. Crosstalk between Kaiso, 
Kaiso–p120ctn, ǃ-catenin and Endossomal compartments.  a. In the absence of Wnt ligands 
or in the case of high E-cadherin concentrations, ǃ-catenin and p120ctn associate with E-
cadherin, promoting intercellular adhesion. b. In the absence of Wnt binding, a 
macromolecular complex formed by the cytoplasmic protein APC (adenomatous polyposis 
coli), Axin and disheveled (DSH) stimulate the phosphorylation of ǃ-catenin. Directly 
responsible for this phosphorylation is the protein casein kinase 1 (CK1) and glycogen 
synthase kinase 3 (GSK3). Β-catenin phosphorylated is destined to a ubiquitin-mediated 
degradation of ǃ-catenin. c. The activation of canonical pathway leads to stabilization of ǃ 
catenin. Therefore, Wnt signaling would finally prevent ǃ-catenin degradation, which could 
then (d.) translocate to the nucleus, and perform its transcriptional activity, associate with 
lymphoid enhancer-binding protein (LEF)/T-cell factor (TCF). e. If E-cadherin is mutated or 
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downregulated, p120ctn become at least partly cytoplasmic. Cytoplasmic p120ctn is stable 
and modulates small GTPases by stimulating RAC and inhibiting RHO. Both small GTPases 
are stimulated by non-canonical Wnt signalling.  f. Kaiso translocate into the nucleus and 
within the nucleus kaiso associates with co-repressors (N-CoR) and histone deacetylases 
(HDAC) and represses genes harbouring KBS (Kaiso-binding sites) or methylated CpG 
(mCpG) islands in their regulatory domain. Likewise, a NCoR complex with lymphoid 
enhancer-binding protein (LEF)/T-cell factor (TCF) represses genes with a LEF binding 
sequence (LBS). g. Translocation of Kaiso in the nucleus and vice versa is mainly under the 
influence of microenvironmental factors. h. The protein complexes involving the Wnt 
receptor, Gsk3 and CK1 (among others), are then taken inside the lumen of the 
multivesicular bodies (MVBs), separating Gsk3 from their cytoplasmic substrates and it also 
produces the stabilization of ǃ-catenin. APC, adenometous polyposis coli protein; 
BTB/POZ, broad-complex, tramtrak and bric-a-brac/poxvirus and zinc finger domain; 
DAAM1, Dishevelled-associated activator of morphogenesis 1; GBP, GSK3-binding protein; 
LRP, LDL-receptor-related protein (Wnt co-receptor). Wnt signalling pathway modified 
from Van Roy & McCrea, 2005. 
11. Kaiso  
This protein has been recently considered revolutionary due to its multifunctional role, 
modulating cytoplasmic processes and fulfilling transcriptional functions. It has the specific 
ability to interact with methylated DNA configuring an interesting pharmacological target 
for molecules that participate in the interphase of the epigenome.  It is also known to be 
decisive in the process of tumorigenesis, and cytoplasmic accumulation of this protein, such 
as detection by IMH, plays an important role in the prognosis of some cancers. Because of 
these important reasons, the impact produced by this protein in a new scenario in epigenetic 
cancer shall deserve greater consideration.  
Kaiso protein (encoded by the zinc finger and broad-complex, tramtrack and bric-a-brac 
(BTB)-domain-containing 33 gene ZBTB33) is a transcriptional factor that has a BTB/POX 
domain for the protein-protein interaction in the amino-terminal portion and a “Zinc 
Finger” domain for interaction with DNA in the carboxyl-terminal portion (Collins et al., 
2001; Daniel & Reynolds, 1999).  Due to the aforementioned characteristics Kaiso is member 
of a subfamily of "zinc finger" proteins known as POZ-ZF (Daniel & Reynolds, 1999). Most 
members of this subfamily (POZ-ZF) transcriptional factors including, Kaiso, BCL-6, PLZF, 
HIC-1, FAZF, APM1, MIZ-1, ZBTB7 and champignon are involved in the process of cancer 
development (Bardwell  & Treisman, 1994; Albagli et al., 1995; Wales  et al., 1995; Schneider 
et al., 1997; Reuter et al., 1998; Hoatlin et al., 1999; Maeda et al., 2005a). 
Kaiso protein interacts specifically with p120 catenin (p120ctn), a member of the armadillo 
family that owns ǃ-catenin (Daniel & Reynolds, 1999). ǃ-catenin and p120ctn are very 
similar molecules possessing the two i. domains of interaction with the cytosolic portion of 
cadherins and ii. the ability to translocate from the cytoplasm to the nucleus (Reynolds & 
Roczniak-Ferguson, 2004). A p120ctn is a regulator of the kaiso function and it is known that 
in the nucleus of the cell they directly modulate the action of canonical Wnt pathways and 
target genes of ǃ-catenin, which is another indication of the importance of Kaiso in the 
development of cancer (Daniel, 2007).   
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The genes transcriptionally regulated by Kaiso are matrilysin (Spring et al., 2005), c-myc and 
cyclin D1 (Van Roy & McCrea, 2005), all of them widely known for their involvement in cell 
proliferation and metastasis and all also regulated by the domain "Zinc finger" of Kaiso 
(Daniel, 2007). Gene Wnt11 is another important and well- known regulatory target, which 
belongs to the non-canonical Wnt pathways (Kim et al., 2004). 
The non-canonical Wnt pathways are involved in cell polarity and cell movements of 
epithelial-mesenchymal transition observed during gastrulation, and also during the 
process of metastasis (Wallingford et al., 2002; Veeman et al., 2003). The cytoplasmic 
molecules involved in the transduction of non-canonical Wnt pathway are DSH 
(Dishevelled) and DAAM1 (Dishevelled-associated activator of morphogenesis 1) (Habas et 
al., 2001) that through two independent and parallel pathways lead to activation of 
GTPases, Rho (Marlow et al., 2002; Habas et al., 2001) and Rac (Habas et al., 2003)(Figure 1 
e). Ultimately, the activation of a kinase assorted to the Rho called ROCK would be 
responsible for the reorganization of the cytoskeleton (Veeman et al., 2003). p120ctn 
regulates the cell cytoplasm proteins Rho and Rac (Van Roy & McCrea, 2005) and Kaiso 
would be indirectly related to processes that involve reorganization of the cytoskeleton 
during metastasis. 
The Kaiso protein, unlike other members of the subfamily, appears to be the only factor with 
bimodal features in their interaction with DNA, being able to interact specifically with 
methylated CpG island sites and with consensus DNA sequences CTGCNA (Prokhortchouk 
et al., 2001; Daniel et al., 2002) (Figure 1 f). These interactions are important for the 
epigenetic silencing of tumor suppressor genes, which is an essential role of Kaiso in colon 
cancer development processes (Lopes et al., 2008). 
Regarding epigenetic silencing, the Kaiso protein also acts as a histone-deacetylase-
dependent transcriptional repressor (Daniel, 2007). The HDAC (histone deacetylase) 
catalyzes the deacetylation of histones and these changes facilitate more closed chromatin 
conformation and restrict gene transcription. The HDAC acts as a protein complex with 
corepressors recruited. Some of them are directly recruited by Kaiso as NCOR1 (nuclear 
receptor co-repressor 1) (Yoon et al., 2003) and SIN3A (Van Roy & McCrea, 2005) (Figure 1f). 
The information on repression of target genes of the canonical and non-canonical Wnt 
pathways, associated with cancer (including matrilysin and Wnt11) can lead us to think that 
the role of Kaiso in the healthy cell is that of a tumor suppressor gene.  
12. Kaiso and tumorigenesis 
Almost all the members of the POZ-ZF family were found to be involved in cancer 
development. BCL-6 and PLZF are oncoproteins linked to non-Hodgkin’s lymphoma and 
acute promyelocytic leukemia, respectively (Chen et al., 1994; Onizuka et al., 1995). FAZF 
and ZBTB7 are related to Fanconi’s anemia and several other human cancers (Hoatlin et al., 
1999; Maeda et al., 2005b; Dai et al., 2002; Pessler et al., 1997). On the other hand, ICH-6 and 
APM1 are candidate tumor suppressors in various human cancers (Schneider et al., 1997; 
Albagli, 2003). 
Like other members of the subfamily POZ-ZF, the Kaiso protein has been implicated in 
cancer and the first indirect evidence emerged because the target genes of the Kaiso protein 
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(MTA2, MMP2, and siamois CiclinD1) are linked to cell proliferation or metastasis tumor, 
providing a good indication of the importance, though indirect, of Kaiso in tumorigenesis 
processes. 
More consistent and direct data about the participation of Kaiso in the  cancer development 
process have been recently obtained, when it has been found that Kaiso inhibits activation 
mediated by ǃ-catenin of the Mmp7 gene (also known as matrilysin), which is well known 
for metastatic spread (Spring et al., 2005). Recently another study suggests that Kaiso can 
regulate TCF/LEF1-activity, via modulating HDAC1 and beta-catenin-complex formation 
(Iioka et al., 2009) (Figure 1f). This shows that Kaiso can directly regulate the signaling 
pathway of canonical Wnt / ǃ-catenin widely known for its involvement in human tumors. 
Other evidence also showed that Kaiso rescues the dorsalization of the mesoderm produced 
by ǃ-catenin and siamois in Xenopus laevis (Park et al., 2005). Siamois is a high mobility 
group (HMG)-box transcription factor that promotes the dorsalization of the mesoderm of 
amphibians and is a well-known target of the canonical Wnt pathway involving TCF/LEF. 
The Kaiso overexpression decreases the ability of TCF/LEF to interact with ǃ-catenin, which 
implies that Kaiso and TCF/LEF are associated in the nucleus (Van Roy & McCrea, 2005). 
Other target genes of canonical Wnt pathway, such as Fos, Myc and CCND1 also appear to 
be directly regulated by Kaiso. On the other hand, the non-canonical Wnt pathways would 
also be modulated by Kaiso, at least in Xenopus, where it has been demonstrated that Kaiso 
depletion directly directly activates the Wnt11 promoter (Kim et al, 2004). 
However, there is still controversy regarding the Kaiso’s oncogenic or tumor suppressor 
role. As aforementioned, it is known that matrilysin and Wnt11 are repressed  by Kaiso, 
and, thus, it is believed that it might act as a tumor suppressor (Dai et al., 2009).  
Nevertheless, Kaiso could also act as a methylation-dependent oncogene, repressing the 
tumor suppressor gene CDKN2A and providing increased survival of colon cancer cells 
(Lopes et al., 2008). The epigenetic silencing role of kaiso was approached to produce a 
depletion of Kaiso (by RNA interference) and an increased expression of the tumor 
suppressor gene CDKN2 was found, which did not affect the DNA methylation levels. As a 
result, the colon cancer cells were more susceptible to cell death mediated by chemotherapy 
(Lopes et al., 2008). It is then possible to assess the importance of kaiso as a possible 
therapeutical target to improve the efficiency of the current cancer treatments.  
13. Subcellular localization of Kaiso and prognosis of cancer 
As expected for a transcriptional factor, the Kaiso protein is often found in the nucleus of 
several tumor or non-tumor derived mammalian cell lines (Daniel, 2007). Recent studies 
using  immunohistochemistry analysis of normal and tumor tissue revealed that Kaiso 
protein is predominantly localized in the cytoplasm of the cell or is totally absent, though 
(Soubry  et al., 2005). 
This seems to be unusual because Kaiso has a signal "NLS" highly conserved and required 
for any protein with nuclear localization. Moreover, Kaiso uses classical nuclear transport 
mechanisms through interaction with Importin ǂ/ǃ nuclear (Kelly et al., 2004). One 
possible explanation is that Kaiso, like other proteins or factors that normally reside in the 
cytoplasm, require a post-translational modification, to be targeted and translocated to the 
cell nucleus.  
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However, 2009 data has shown for the first time that the subcellular localization of Kaiso in 
the cytoplasm of a cell is directly associated with the poor prognosis of patients with lung 
cancer (non-small cell), and around 85 to 95% of lung cancers are non-small cell (Dai et al., 
2009). Such data shows a direct relationship between the clinical profile of patients with 
pathological expression of Kaiso. Therefore, evidence of changes in subcellular localization 
seems to be relevant to the diagnosis and prognosis of various types of human tumors. 
14. Analysis of the subcellular location of Kaiso in Mielode Chronic Leukemia 
(CML) 
Data obtained by our group in collaboration with the laboratory of stem cells of the 
Brazilian National Cancer Institute (INCA of Rio de Janeiro), headed by Dr. Eliana 
Abdelhay, shows the subcellular distribution of Kaiso by immunofluorescence on cell lines 
K562, used as a model of CML in the blastic phase. As it can be seen in Figure 2a, the 
expression of Kaiso is clearly cytoplasmic (Cofre, J., personal communications). As expected, 
cytoplasmic expression is significantly reduced when using the duplex for inhibition of 
Kaiso (Rnai) 48 hours after transfection (Figure 2b). As a control, we used the ǃ-tubulin 
marker and demonstrated that the duplex Kaiso does not modify the expression of this 
marker after transfection for 48 hours (Figure 2 c and d) . 
 
Fig. 2. Immunofluorescence analysis of kaiso expression. A.Kaiso was expressed in the 
cytoplasm of K562 cells (a human erythroleukemic line). B. siRNA-Kaiso efficiently down-
regulates cytoplasm expression after 48 hours transfection. As a control, we used the marker 
beta-tubulin and showed that siRNA-Kaiso does not modify the expression of this marker 
after 48 hours transfection. 
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These results are promising, first because they make it possible to relate the LMC disease to 
the presence of cytoplasmic Kaiso, and second, because the molecule may have a diagnostic 
value of clinical interest, not only in LMC, but also in other types of leukemia.  
15. The new view of cellular compartments 
Another noteworthy aspect is that the cellular compartments are currently the object of 
many discussions in experimental biology, and we are witnessing a reconceptualization  of 
these compartments, which involves the way they are structured and work, as well as their 
possible relationships with disease development at the cellular level.   
It is logical to think that since a cell is in a process of constant division, for any given cell 
division, the elements in the nucleus and the cytoplasm are mixed, and at this important 
moment for cellular functioning, the cytoplasmic and nuclear components share the same 
general compartment that is the cytoplasm of the cell under division. According to this 
view, there is a very tenuous separation between the cytoplasm and the nucleus of a cell, 
and the sub compartments generated inside the cytoplasm are what really matters in a cell. 
Although many scenarios of the separation of specific functions have been detected inside 
the nucleus (Zhao et al., 2009; Spector & Lamond, 2011), none of these microenvironments 
would be maintained in cells in the process of cell division. 
These new sub compartments that are important for the understanding of the mechanisms 
of diseases such as cancer are the networks of endocytic membrane represented by a system 
of interconnected membranous organelles and endosomes that are responsible for the 
selection of destination and transport of various types of macromolecules from the 
extracellular milieu into the cell and within the cell. A recent discovery reveals that the 
process of endocytosis and endosomes would be crucial for the maintenance of cellular 
homeostasis, ensuring the compartmentalization of transduction processes of intracellular 
signals (Scita & Di Fiore, 2010). It is now widely accepted that systems of endocytic 
membrane trafficking and intracellular signaling are closely interconnected and endosomes 
could act as signaling platforms (Hupalowska & Miaczynska, 2011). 
The main endosomal compartment that regulates intracellular signaling processes would be 
the so-called multivesicular bodies (MVB). It would have a specific role in the sequestration 
of receptors activated in the membrane that by means of an intracellular mechanism of 
endocytosis would be placed inside the lumen of the MVB, unable to access the components 
of intracellular signaling, which would reduce and negatively regulate the signaling 
pathway of these receptors (Katzmann et al., 2002; Raiborg & Stenmark, 2009). 
Surprisingly, this compartment can also play a role in positive regulation of certain 
signaling pathways through sequestration of inhibitors (Taelman et al., 2010). Because of its 
important role in cancer, it is worth mentioning that the Gsk3 and CK1 promoted by the 
Wnt signaling pathways would be hidden in internal vesicles inside the MVB. The protein 
complexes involving the Wnt receptor, Gsk3 and CK1 (among others), are then taken inside 
the lumen of the MVB, separating Gsk3 from their cytoplasmic substrates (Figure 1h). 
Consequently, in the absence of Gsk3, which is now inside the MVB, ǃ-catenin would be 
stabilized in the cytoplasm, translocate into the nucleus and activate transcription. 
The endosomal compartments are, thus, a trapping mechanism of enzyme and receptors, 
and it is believed that it produces the stabilization of many cellular proteins. Coincidentally, 
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as discussed in the chapter, proteins as connexin and Kaiso, which are essential for the 
diagnosis and prognosis of cancer, are always accumulated in the cytoplasm in cancer cells. 
This knowledge of endosomal compartments can be of paramount importance for the 
understanding of the molecular mechanisms by which diseases such as cancer initiate. For 
example, in the case of specific connexins, the tumor suppressor role could be related to the 
sequestration of these proteins in MVB during the onset of this tumor. Other related studies 
have proposed connexins as platforms for sequestering signaling proteins, suggesting that 
connexins might directly sequester MAPK (Mitogen-Activated Protein Kinase), CDK 
(Cyclin-dependent kinase), and Src (Proto-oncogene tyrosine-protein kinase) by SH2 and 
SH3 domains of the carboxyl terminal tail of Cx43 and, thus, act as a tumor suppressor 
(Cofre & Bermudez, 2011). 
No studies have shown the association of connexins and endosomal compartments, and yet 
such studies could help understand the controversy of the expression of connexins in the 
plasma membrane during early metastasis, which can be related to deregulation 
mechanisms of cellular physiology of the endocytic compartment. 
16. Future directions 
Therefore, a view focused on subcellular compartments and proteins modulating the 
epigenome can provide a greater understanding of the biology of malignant cells, as well as 
improve our approach to cancer treatment. It is known that cancer treatment is dictated by 
the stage of the disease, and that cancer treatment is more effective during the chronic phase 
of the disease. Unfortunately, clinical and molecular tests cannot predict disease 
progression, which can create an obstacle to diagnosis: the inability to identify subtypes of 
patients most likely to benefit from specific treatment options for specific stages of the 
disease, which would make it possible to offer a therapy targeted to a given cancer patient. 
Finally, the understanding of this new biology of disease progression can provide markers 
for clinical diagnosis and different approximations for better therapeutic strategies. Also, 
there is always hope that we’ll be able to identify proteins and signaling pathways that may 
be useful as reliable prognostic markers of the disease and therapeutic targets in the near 
future.   
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